Advertisement

Comparative pharmacokinetics and pharmacodynamics of eterobarbital and phenobarbital in normal volunteers

  • N. Barzaghi
  • G. Gatti
  • R. Manni
  • C. A. Galimberti
  • C. Zucca
  • E. Perucca
  • A. Tartara
Article

Summary

The comparative pharmacokinetics and pharmacodynamics of single oral doses of eterobarbital (N, N′-dimethoxymethylphenobarbital, DMMP, 400 mg) and phenobarbital (200 mg) were evaluated in a double-blind study in 8 normal volunteers. Following administration of DMMP, no unchanged drug could be detected in serum. The active monomethoxymethyl metabolite (MMP) appeared rapidly in the circulation but its concentration remained generally low and declined below the limit of detection (0.5 μg/ml) usually before 9.5 h. Serum levels of DMMP-derived PB increased slowly and reached a peak between 24 and 48 h in most cases. One subject showed an atypical pharmacokinetic profile, characterized by relatively high levels of MMP and a delayed appearance of low levels of PB. After administration of PB, serum drug levels peaked within 1.5 h and remained, at all sampling times, higher than those observed after intake of DMMP. Compared with DMMP, PB induced greater sedative effects as assessed by visual analogue rating scale, critical flicker fusion frequency and multiple sleep latency tests.

Keywords

Phenobarbital eterobarbital pharmacokinetics pharmacodynamics Multiple Sleep Latency Tests (MSLTs) man 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vida J., Hooker L., Reinhard J. (1973): Anticonvulsant III: phenobarbital and mephobarbital derivatives, J. Med. Chem, 16, 602–605.CrossRefPubMedGoogle Scholar
  2. 2.
    Samour C., Vida J. (1973): Anticonvulsant I. Alkoxymethyl derivatives of barbiturates and diphenylhydantoin. J. Med. Chem., 16, 602–605.CrossRefGoogle Scholar
  3. 3.
    Gallagher B., Woodbury S. (1975): A double-blind comparison of the anticonvulsants dimethoxymethylphenobarbital and phenobarbital. In: Janz D. (ed). Epileptology. Stuttgart, Georg Thieme, pp. 117–122.Google Scholar
  4. 4.
    Gallagher B., Baumel I., Woodbury S., Dimicco J. (1975): Clinical evaluation of eterobarb, a new anticonvulsant. Neurology, 25, 399–404.PubMedGoogle Scholar
  5. 5.
    Smith D.B., Goldstein S.G., Roomet A. (1986): A comparison of the toxicity effects of the anticonvulsant eterobarb (Antilon, DMMP) and phenobarbital in normal human volunteers. Epilepsia, 27, 149–155.CrossRefPubMedGoogle Scholar
  6. 6.
    Freer L.S. (1979): Characterization of the functional tolerance development to N,N3-dimethoxymethylphenobarbital (PhD Thesis). Washington DC, Georgetown University, pp. 1–268.Google Scholar
  7. 7.
    Mattson R.H., Williamson P.D., Hanahan E. (1976): Eterobarb therapy in epilepsy. Neurology, 26, 1014–1017.PubMedGoogle Scholar
  8. 8.
    D’Angelo L, Grimaldi R, Caravaggi M, et al. (1986): A double-blind placebo controlled clinical study on the effect of a standardized ginseng extract on psychomotor performance in healthy volunteers. J. Ethnopharmacol., 16, 15–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Hindmarch I. (1980): Psychomotor function and psychomotor drugs. Br. J. Clin. Pharmacol, 10, 189–209.PubMedGoogle Scholar
  10. 10.
    MacPhee G.J.A., Goldie C., Roulston D., et al. (1986): Effect of carbamazepine on psychomotor performance in naive subjects. Eur. J. Clin. Pharmacol., 30, 37–42.CrossRefPubMedGoogle Scholar
  11. 11.
    MacPhee G.J.A., Mitchell J.R., Wiseman L., et al. (1988): Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man. Br. J. Clin. Pharmacol., 25, 59–66.PubMedGoogle Scholar
  12. 12.
    Dement W., Seidel W., Carskadon M. (1982): Daytime alertness, insomnia and benzodiazepines. Sleep, 5, S28-S45.PubMedGoogle Scholar
  13. 13.
    Rechtschaffen A., Kales A. (1986): A Manual of Standardized Terminology, Techniques and Scoring Systems for Sleep Stages of Human Subjects. Los Angeles, University of CaliforniaGoogle Scholar
  14. 14.
    Perucca E., Gatti G., Frigo G.M., et al. (1978): Disposition of sodium valproate in epileptic patients. Br. J. Clin. Pharmacol, 5, 495–499.PubMedGoogle Scholar
  15. 15.
    Goldberg M., Gal J., Cho A.K., Jenden D.J. (1976): Metabolism of dimethoxymethylphenobarbital (eterobarb) in patients with epilepsy. Ann. Neurol, 5, 121–126.CrossRefGoogle Scholar
  16. 16.
    Matsumoto I.T., Gallagher B.B. (1975): Metabolism and excretion of C14-eterobarb in epileptic patients. In: Janz D. (ed). Epileptology. Stuttgart, Georg Thieme, pp. 122–129.Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • N. Barzaghi
    • 1
  • G. Gatti
    • 1
  • R. Manni
    • 2
  • C. A. Galimberti
    • 2
  • C. Zucca
    • 2
  • E. Perucca
    • 1
  • A. Tartara
    • 2
  1. 1.Department of Medical PharmacologyUniversity of PaviaPaviaItaly
  2. 2.Department of NeurologyUniversity of PaviaPaviaItaly

Personalised recommendations